{
    "name": "paliperidone",
    "comment": "Rx",
    "other_names": [
        "Invega",
        "Invega Sustenna",
        "Invega Trinza",
        "Invega Hafyera"
    ],
    "classes": [
        "Antipsychotics",
        "2nd Generation"
    ],
    "source": "https://reference.medscape.com/drug/invega-sustenna-invega-trinza-paliperidone-342992",
    "pregnancy": {
        "common": [
            "Neonates exposed to antipsychotic drugs during third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery ",
            "Available data of pregnant females exposed to paliperidone have not established a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Drug detected in plasma in adults up to 18 months after a single 3-month paliperidone injection; clinical significance administered before pregnancy or anytime during pregnancy is unknown"
        ],
        "specific": [
            {
                "type": "Pregnancy exposure registry",
                "description": [
                    "Monitors pregnancy outcomes in females exposed to atypical antipsychotics during pregnancy",
                    "Register patients by contacting the National Pregnancy Registry for atypical antipsychotics at 1-866-961-2388 or online at "
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "There are risks to the mother associated with untreated schizophrenia and with exposure to antipsychotics during pregnancy",
                    "Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder have been reported in neonates who were exposed to antipsychotic drugs; monitor for extrapyramidal and/or withdrawal symptoms and manage appropriately"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Based on pharmacologic action of paliperidone (D2 receptor antagonism), treatment may result in an increase in serum prolactin levels, which may lead to a reversible reduction in fertility in females of reproductive potential"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Limited data from published literature report presence of paliperidone in human breast milk",
            "There is no information on effects on breastfed infant, or on milk production",
            "Sedation, failure to thrive, jitteriness, and extrapyramidal symptoms (tremors and abnormal muscle movements) reported in breastfed infants exposed to risperidone (parent compound of paliperidone) ",
            "Monitor infants exposed to treatment through breast milk for excess sedation, failure to thrive, jitteriness, and extrapyramidal symptoms (tremors and abnormal muscle movements)"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Increased mortality in elderly patients with dementia-related psychosis",
                    "description": [
                        "Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death",
                        "Not approved for use in patients with dementia-related psychosis"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Documented hypersensitivity to paliperidone or risperidone"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Increased incidence of cerebrovascular adverse reactions (eg, stroke, transient ischemic attack, including fatalities) reported ",
                "Neuroleptic malignant syndrome (NMS) reported in association with antipsychotic drugs; if NMS is suspected, discontinue treatment and provide symptomatic treatment and monitoring",
                "May induce orthostatic hypotension; use with caution in patients with known cardiovascular or cerebrovascular disease and patients predisposed to hypotension",
                "Motor instability, somnolence, and orthostatic hypotension reported, which may lead to falls and, consequently, fractures or other fall-related injuries; assess risk of falls when initiating treatment and recurrently for patients receiving repeated doses, particularly the elderly, with diseases, conditions, or medications that could exacerbate these effects",
                "Hyperprolactinemia reported; may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotrophin secretion and gonadal steroidogenesis in female and male patients; galactorrhea, amenorrhea, gynecomastia, and impotence reported; long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects",
                "May cause CNS depression (somnolence, sedation, dizziness), which may impair abilities to perform tasks requiring mental alertness, including operating heavy machinery",
                "Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold",
                "Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of aspiration pneumonia",
                "Rare cases of priapism reported",
                "Use caution when prescribing to patients who will be experiencing conditions which may contribute to elevation in core body temperature (eg, exercising strenuously, extreme heat exposure, concomitant medication with anticholinergic activity, dehydration)",
                "Avoid use in severe preexisting GI stenosis",
                "Rare cases of intraoperative floppy iris syndrome reported with risperidone in patients undergoing cataract surgery; paliperidone is active metabolite of risperidone; use caution; benefits or risks of interrupting paliperidone or risperidone use prior to cataract surgery not established",
                "Patients with Parkinson disease may be more sensitive to CNS and extrapyramidal effects",
                "May mask toxicity of other drugs or conditions (eg, intestinal obstruction) due to antiemetic effects",
                "May increase risk of death in elderly patients with dementia-related psychosis ",
                "Use caution in patients with history of suicidal ideation or any form of psychotic illness; may increase risk of suicide attempt",
                "Certain circumstances may increase risk of the occurrence of Torsades de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including bradycardia; hypokalemia or hypomagnesemia; concomitant use of other drugs that prolong the QTc interval; and presence of congenital prolongation of the QT interval",
                "Patient should see healthcare provider or go to the nearest emergency room right away if erection lasts more than 4 hr"
            ],
            "specific": [
                {
                    "type": "Tardive dyskinesia",
                    "description": [
                        "Tardive dyskinesia may develop",
                        "Risk of developing tardive dyskinesia and likelihood that it will become irreversible appears to increase with duration of treatment and cumulative dose; syndrome may develop after relatively brief treatment periods or after discontinuing treatment",
                        "May remit, partially or completely, if treatment withdrawn; antipsychotic treatment may suppress (or partially suppress) signs and symptoms of syndrome and thereby possibly mask underlying process",
                        "Reserve chronic antipsychotic treatment for patients who suffer from a chronic illness known to respond to antipsychotic drugs, and for whom alternative are not available or appropriate",
                        "In patients who require chronic treatment, use lowest dose and the shortest duration of treatment producing a satisfactory clinical response; periodically reassess need for continued treatment"
                    ]
                },
                {
                    "type": "Metabolic changes",
                    "description": [
                        "Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular or cerebrovascular risk (eg, hyperglycemia, dyslipidemia, hyperprolactinemia, body weight gain)",
                        "Hyperglycemia and diabetes mellitus (DM), in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, have also been reported",
                        "Regularly monitor patients diagnosed with DM who started an atypical antipsychotic for worsening of glucose control",
                        "Patients with risk factors for DM (eg, obesity, family history of diabetes) who are starting treatment should undergo fasting blood glucose testing upon initiation and periodically during treatment",
                        "Monitor any patient treated with atypical antipsychotics for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness"
                    ]
                },
                {
                    "type": "Leukopenia, neutropenia, and agranulocytosis",
                    "description": [
                        "Leukopenia/neutropenia and agranulocytosis reported",
                        "Possible risk factors for leukopenia/neutropenia include preexisting low white blood cell (WBC) count and history of drug-induced leukopenia/neutropenia",
                        "Monitor patients with clinically significant neutropenia for fever or other symptoms or signs of infection and treat promptly if such symptoms or signs occur",
                        "If history of clinically significant low WBC count or drug-induced leukopenia/neutropenia, monitor complete blood cell count (CBC) frequently during first few months of therapy; discontinue if WBC decline <1000/ mm",
                        "3",
                        " and continue monitoring WBC until recovery"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Substrate of P-gp and CYP3A4",
                        "Centrally-acting drugs and alcohol",
                        "Use with caution",
                        "Centrally-acting drugs and alcohol may modulate the CNS effects of paliperidone",
                        "Drugs that cause orthostatic hypotension",
                        "Monitor orthostatic vital signs in patients who are vulnerable to hypertension",
                        "Drugs that induce orthostatic hypotension may enhance the orthostatic hypotensive effects of paliperidone",
                        "Strong CYP3A4 and P-gp inducers (Invega Hafyera only)",
                        "Avoid coadministration of CYP3A4 and/or P-gp inducers",
                        "If a strong inducer is necessary, consider using paliperidone extended-release tablets",
                        "Levodopa and other dopamine agonists",
                        "Monitor and manage appropriately",
                        "Paliperidone may antagonize the effect of levodopa and other dopamine agonists",
                        "Drugs that prolong QT interval",
                        "Avoid coadministration with other drugs that are known to prolong QTc including Class 1A (eg, quinidine, procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (eg, chlorpromazine, thioridazine), fluoroquinolones (eg, moxifloxacin), or any other class of medications known to prolong the QTc interval",
                        "Paliperidone may enhance the QT-prolonging effects of such drugs"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "amisulpride",
            "description": {
                "common": "amisulpride, paliperidone.\nEither increases toxicity of the other by Other (see comment). Contraindicated. \nComment: Increases risk of neuroleptic malignant syndrome."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "goserelin",
            "description": {
                "common": "goserelin increases toxicity of paliperidone by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "leuprolide",
            "description": {
                "common": "leuprolide increases toxicity of paliperidone by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adagrasib",
            "description": {
                "common": "adagrasib, paliperidone.\nEither decreases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "afatinib",
            "description": {
                "common": "paliperidone increases levels of afatinib by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Reduce afatinib daily dose by 10 mg if not tolerated when coadministered with P-gp inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "alfuzosin",
            "description": {
                "common": "alfuzosin and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amisulpride",
            "description": {
                "common": "amisulpride and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anagrelide",
            "description": {
                "common": "anagrelide and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apomorphine",
            "description": {
                "common": "paliperidone decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "aripiprazole and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "arsenic trioxide",
            "description": {
                "common": "arsenic trioxide and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "artemether",
            "description": {
                "common": "artemether and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "asenapine transdermal",
            "description": {
                "common": "asenapine transdermal and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atomoxetine",
            "description": {
                "common": "atomoxetine and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "benzhydrocodone/acetaminophen, paliperidone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bromocriptine",
            "description": {
                "common": "paliperidone decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine",
            "description": {
                "common": "buprenorphine and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine buccal",
            "description": {
                "common": "buprenorphine buccal and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine subdermal implant",
            "description": {
                "common": "buprenorphine subdermal implant and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine transdermal",
            "description": {
                "common": "buprenorphine transdermal and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine, long-acting injection",
            "description": {
                "common": "buprenorphine, long-acting injection and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cabergoline",
            "description": {
                "common": "paliperidone decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "calcium/magnesium/potassium/sodium oxybates",
            "description": {
                "common": "paliperidone, calcium/magnesium/potassium/sodium oxybates.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ceritinib",
            "description": {
                "common": "ceritinib and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clozapine",
            "description": {
                "common": "clozapine and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "degarelix",
            "description": {
                "common": "degarelix and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "desflurane",
            "description": {
                "common": "desflurane and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "disopyramide",
            "description": {
                "common": "disopyramide and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "donepezil",
            "description": {
                "common": "donepezil and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dopamine",
            "description": {
                "common": "paliperidone decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "edoxaban",
            "description": {
                "common": "paliperidone will increase the level or effect of edoxaban by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Dose adjustment may be required with strong P-gp inhibitors. DVT/PE treatment: Decrease dose to 30 mg PO once daily. NVAF: No dose reduction recommended"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eliglustat",
            "description": {
                "common": "eliglustat and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug. Encorafenib is associated with dose-dependent QTc interval prolongation. Avoid with drugs known to prolong QT interval."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "entrectinib",
            "description": {
                "common": "paliperidone and entrectinib both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erdafitinib",
            "description": {
                "common": "erdafitinib will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If coadministration unavoidable, separate administration by at least 6 hr before or after administration of P-gp substrates with narrow therapeutic index."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eribulin",
            "description": {
                "common": "eribulin and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "escitalopram",
            "description": {
                "common": "escitalopram increases toxicity of paliperidone by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fingolimod",
            "description": {
                "common": "fingolimod and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gilteritinib",
            "description": {
                "common": "gilteritinib and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glasdegib",
            "description": {
                "common": "paliperidone and glasdegib both increase  QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "granisetron",
            "description": {
                "common": "granisetron and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "histrelin",
            "description": {
                "common": "histrelin increases toxicity of paliperidone by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydrocodone",
            "description": {
                "common": "hydrocodone, paliperidone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxychloroquine sulfate",
            "description": {
                "common": "hydroxychloroquine sulfate and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxyzine",
            "description": {
                "common": "hydroxyzine and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ibutilide",
            "description": {
                "common": "ibutilide and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "indapamide",
            "description": {
                "common": "indapamide and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "inotuzumab",
            "description": {
                "common": "inotuzumab and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isoflurane",
            "description": {
                "common": "isoflurane and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "ivosidenib and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lasmiditan",
            "description": {
                "common": "lasmiditan increases levels of paliperidone by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lefamulin",
            "description": {
                "common": "lefamulin and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levodopa",
            "description": {
                "common": "paliperidone decreases effects of levodopa by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levodopa inhaled",
            "description": {
                "common": "paliperidone decreases effects of levodopa inhaled by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Atypical (2nd generation) antipsychotics inhibit dopamine D2 receptors in varying degrees (clozapine and quetiapine are lower risk). ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisuride",
            "description": {
                "common": "paliperidone decreases effects of lisuride by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lithium",
            "description": {
                "common": "lithium and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "macimorelin",
            "description": {
                "common": "macimorelin and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mefloquine",
            "description": {
                "common": "mefloquine increases toxicity of paliperidone by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methyldopa",
            "description": {
                "common": "paliperidone decreases effects of methyldopa by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoclopramide intranasal",
            "description": {
                "common": "paliperidone, metoclopramide intranasal.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "mirtazapine and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mobocertinib",
            "description": {
                "common": "mobocertinib and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olanzapine",
            "description": {
                "common": "olanzapine and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olopatadine intranasal",
            "description": {
                "common": "paliperidone and olopatadine intranasal both increase  sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ondansetron",
            "description": {
                "common": "paliperidone and ondansetron both increase  QTc interval. Avoid or Use Alternate Drug.  Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin will increase the level or effect of paliperidone by  Other (see comment). Avoid or Use Alternate Drug. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "panobinostat",
            "description": {
                "common": "paliperidone and panobinostat both increase  QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pentamidine",
            "description": {
                "common": "paliperidone and pentamidine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pimavanserin",
            "description": {
                "common": "paliperidone and pimavanserin both increase  QTc interval. Avoid or Use Alternate Drug. Coadministration may increase the risk of QT prolongation and cardiac arrhythmia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pimozide",
            "description": {
                "common": "paliperidone and pimozide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pitolisant",
            "description": {
                "common": "paliperidone and pitolisant both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pomalidomide",
            "description": {
                "common": "paliperidone increases levels of pomalidomide by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pramipexole",
            "description": {
                "common": "paliperidone decreases effects of pramipexole by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "primaquine",
            "description": {
                "common": "primaquine and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "procainamide",
            "description": {
                "common": "paliperidone and procainamide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quinidine",
            "description": {
                "common": "quinidine will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ribociclib",
            "description": {
                "common": "ribociclib and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "riociguat",
            "description": {
                "common": "paliperidone will increase the level or effect of riociguat by  decreasing metabolism. Avoid or Use Alternate Drug. Coadministration of riociguat (substrate of CYP isoenzymes 1A1, 2C8, 3A, 2J2) with strong CYP inhibitors may require a decreased initial dose of 0.5 mg PO TID; monitor for signs of hypotension and reduce dose if needed"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "romidepsin",
            "description": {
                "common": "paliperidone and romidepsin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropinirole",
            "description": {
                "common": "paliperidone decreases effects of ropinirole by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "safinamide",
            "description": {
                "common": "paliperidone decreases effects of safinamide by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Dopamine antagonists may decrease safinamide effects and exacerbate Parkinson disease symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir, paliperidone.\nEither increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Increased risk of QT prolongation and cardiac arrhythmias."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "selinexor",
            "description": {
                "common": "selinexor, paliperidone. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sevoflurane",
            "description": {
                "common": "sevoflurane and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sodium oxybate",
            "description": {
                "common": "paliperidone, sodium oxybate.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "solifenacin",
            "description": {
                "common": "solifenacin and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sotalol",
            "description": {
                "common": "paliperidone and sotalol both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sotorasib",
            "description": {
                "common": "sotorasib will decrease the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If use is unavoidable, refer to the prescribing information of the P-gp substrate for dosage modifications."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sufentanil SL",
            "description": {
                "common": "sufentanil SL, paliperidone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sunitinib",
            "description": {
                "common": "sunitinib and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "tacrolimus and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tepotinib",
            "description": {
                "common": "tepotinib will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If concomitant use unavoidable, reduce the P-gp substrate dosage if recommended in its approved product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tetrabenazine",
            "description": {
                "common": "tetrabenazine and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "triptorelin",
            "description": {
                "common": "triptorelin increases toxicity of paliperidone by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "umeclidinium bromide/vilanterol inhaled",
            "description": {
                "common": "paliperidone increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vandetanib",
            "description": {
                "common": "paliperidone, vandetanib.\nEither increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval;  if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vemurafenib",
            "description": {
                "common": "vemurafenib and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that  prolong QT interval is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "venetoclax",
            "description": {
                "common": "paliperidone will increase the level or effect of venetoclax by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If a P-gp inhibitor must be used, reduce the venetoclax dose by at least 50%. Monitor more closely for signs of venetoclax toxicities."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vilanterol/fluticasone furoate inhaled",
            "description": {
                "common": "paliperidone increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vorinostat",
            "description": {
                "common": "vorinostat and paliperidone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abobotulinumtoxinA",
            "description": {
                "common": "abobotulinumtoxinA increases effects of paliperidone by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acarbose",
            "description": {
                "common": "paliperidone, acarbose. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aclidinium",
            "description": {
                "common": "aclidinium decreases levels of paliperidone by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acrivastine",
            "description": {
                "common": "acrivastine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "albiglutide",
            "description": {
                "common": "paliperidone, albiglutide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "albuterol",
            "description": {
                "common": "paliperidone increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfentanil",
            "description": {
                "common": "alfentanil and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfuzosin",
            "description": {
                "common": "paliperidone and alfuzosin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "almotriptan",
            "description": {
                "common": "almotriptan, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alprazolam",
            "description": {
                "common": "alprazolam and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amifostine",
            "description": {
                "common": "amifostine, paliperidone.\nEither increases effects of the other by anti-hypertensive channel blocking. Use Caution/Monitor. Due to its alpha adrenergic antagonism, atypical antipsychotic agents has the potential to enhance the effect of certain antihypertensive agents. Monitor blood pressure and adjust dose accordingly."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "amitriptyline and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxapine",
            "description": {
                "common": "paliperidone and amoxapine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "anticholinergic/sedative combos",
            "description": {
                "common": "anticholinergic/sedative combos decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apomorphine",
            "description": {
                "common": "paliperidone and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "arformoterol",
            "description": {
                "common": "paliperidone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "aripiprazole and paliperidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "armodafinil",
            "description": {
                "common": "paliperidone increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "artemether/lumefantrine",
            "description": {
                "common": "artemether/lumefantrine and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine transdermal",
            "description": {
                "common": "asenapine transdermal and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atorvastatin",
            "description": {
                "common": "atorvastatin will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atracurium",
            "description": {
                "common": "atracurium decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atropine",
            "description": {
                "common": "atropine decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atropine IV/IM",
            "description": {
                "common": "paliperidone increases effects of atropine IV/IM by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "avapritinib and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azelastine",
            "description": {
                "common": "azelastine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "baclofen",
            "description": {
                "common": "baclofen and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bedaquiline",
            "description": {
                "common": "paliperidone and bedaquiline both increase  QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belladonna alkaloids",
            "description": {
                "common": "belladonna alkaloids decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belladonna and opium",
            "description": {
                "common": "belladonna and opium and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benazepril",
            "description": {
                "common": "paliperidone increases toxicity of benazepril by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benperidol",
            "description": {
                "common": "benperidol and paliperidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "benzhydrocodone/acetaminophen and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benzphetamine",
            "description": {
                "common": "paliperidone increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "berotralstat",
            "description": {
                "common": "berotralstat will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor or titrate P-gp substrate dose if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betrixaban",
            "description": {
                "common": "paliperidone increases levels of betrixaban by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Decrease betrixaban dose to 80 mg PO once, then 40 mg PO qDay if coadministered with a P-gp inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bosutinib",
            "description": {
                "common": "bosutinib increases levels of paliperidone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexanolone",
            "description": {
                "common": "brexanolone, paliperidone.\nEither increases toxicity of the other by sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "brexpiprazole and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brompheniramine",
            "description": {
                "common": "brompheniramine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine",
            "description": {
                "common": "buprenorphine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine buccal",
            "description": {
                "common": "buprenorphine buccal and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine, long-acting injection",
            "description": {
                "common": "paliperidone increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butorphanol",
            "description": {
                "common": "butorphanol and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "caffeine",
            "description": {
                "common": "paliperidone increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "captopril",
            "description": {
                "common": "paliperidone, captopril.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Monitor blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Paliperidone dose may need to be increased when coadministered with strong inducers of both CYP3A4 and P-gp"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbinoxamine",
            "description": {
                "common": "carbinoxamine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carisoprodol",
            "description": {
                "common": "carisoprodol and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate, paliperidone.\nEither increases effects of the other by sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ceritinib",
            "description": {
                "common": "paliperidone increases levels of ceritinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloral hydrate",
            "description": {
                "common": "chloral hydrate and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlordiazepoxide",
            "description": {
                "common": "chlordiazepoxide and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloroquine",
            "description": {
                "common": "chloroquine increases toxicity of paliperidone by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpheniramine",
            "description": {
                "common": "chlorpheniramine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "chlorpromazine and paliperidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "paliperidone, chlorpropamide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorzoxazone",
            "description": {
                "common": "chlorzoxazone and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cinnarizine",
            "description": {
                "common": "cinnarizine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "ciprofloxacin and paliperidone both increase  QTc interval. Use Caution/Monitor. Ciprofloxacin elicits minimal effects on QT interval. Caution if used in combination with other drugs known to affect QT interval or in patients with other risk factors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cisatracurium",
            "description": {
                "common": "cisatracurium decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "paliperidone and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clemastine",
            "description": {
                "common": "clemastine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clobazam",
            "description": {
                "common": "paliperidone, clobazam. Other (see comment). Use Caution/Monitor. \nComment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "clomipramine and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonazepam",
            "description": {
                "common": "clonazepam and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonidine",
            "description": {
                "common": "clonidine, paliperidone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clorazepate",
            "description": {
                "common": "clorazepate and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clotrimazole",
            "description": {
                "common": "clotrimazole will decrease the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clozapine",
            "description": {
                "common": "clozapine and paliperidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "codeine",
            "description": {
                "common": "codeine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crizotinib",
            "description": {
                "common": "crizotinib and paliperidone both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclizine",
            "description": {
                "common": "cyclizine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclobenzaprine",
            "description": {
                "common": "cyclobenzaprine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyproheptadine",
            "description": {
                "common": "cyproheptadine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabigatran",
            "description": {
                "common": "paliperidone will increase the level or effect of dabigatran by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Atrial fibrillation: Avoid coadministering dabigatran with P-gp inhibitors if CrCl <30 mL/min.  DVT/PE treatment: Avoid coadministering dabigatran with P-gp inhibitors if CrCl <50 mL/min"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dantrolene",
            "description": {
                "common": "dantrolene and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "daridorexant",
            "description": {
                "common": "paliperidone and daridorexant both increase  sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darifenacin",
            "description": {
                "common": "darifenacin decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dasatinib",
            "description": {
                "common": "dasatinib and paliperidone both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desflurane",
            "description": {
                "common": "desflurane and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desipramine",
            "description": {
                "common": "desipramine and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deutetrabenazine",
            "description": {
                "common": "paliperidone and deutetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely. The risk for parkinsonism, neuroleptic malignant syndrome, and akathisia may be increased by concomitant use of deutetrabenazine and dopamine antagonists or antipsychotics."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexchlorpheniramine",
            "description": {
                "common": "dexchlorpheniramine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexfenfluramine",
            "description": {
                "common": "paliperidone increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexmedetomidine",
            "description": {
                "common": "dexmedetomidine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexmethylphenidate",
            "description": {
                "common": "paliperidone increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextroamphetamine",
            "description": {
                "common": "paliperidone increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextromethorphan",
            "description": {
                "common": "dextromethorphan, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextromoramide",
            "description": {
                "common": "dextromoramide and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diamorphine",
            "description": {
                "common": "diamorphine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam",
            "description": {
                "common": "diazepam and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dicyclomine",
            "description": {
                "common": "dicyclomine decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diethylpropion",
            "description": {
                "common": "paliperidone increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "difelikefalin",
            "description": {
                "common": "difelikefalin and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "difenoxin hcl",
            "description": {
                "common": "difenoxin hcl and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dihydroergotamine",
            "description": {
                "common": "dihydroergotamine, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dimenhydrinate",
            "description": {
                "common": "dimenhydrinate and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diphenhydramine",
            "description": {
                "common": "diphenhydramine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diphenoxylate hcl",
            "description": {
                "common": "diphenoxylate hcl and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dipipanone",
            "description": {
                "common": "dipipanone and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dobutamine",
            "description": {
                "common": "paliperidone increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dofetilide",
            "description": {
                "common": "dofetilide and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dolasetron",
            "description": {
                "common": "dolasetron and paliperidone both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dopamine",
            "description": {
                "common": "paliperidone increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dopexamine",
            "description": {
                "common": "paliperidone increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dosulepin",
            "description": {
                "common": "paliperidone and dosulepin both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin",
            "description": {
                "common": "doxepin and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxylamine",
            "description": {
                "common": "doxylamine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dronedarone",
            "description": {
                "common": "dronedarone will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "droperidol",
            "description": {
                "common": "droperidol and paliperidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elagolix",
            "description": {
                "common": "elagolix will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eletriptan",
            "description": {
                "common": "eletriptan, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eliglustat",
            "description": {
                "common": "eliglustat increases levels of paliperidone by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ephedrine",
            "description": {
                "common": "paliperidone increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epinephrine",
            "description": {
                "common": "epinephrine and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epinephrine racemic",
            "description": {
                "common": "epinephrine racemic and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ergoloid mesylates",
            "description": {
                "common": "ergoloid mesylates, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ergotamine",
            "description": {
                "common": "ergotamine, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "erythromycin base will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "erythromycin ethylsuccinate will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "erythromycin lactobionate will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "erythromycin stearate will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esketamine intranasal",
            "description": {
                "common": "esketamine intranasal, paliperidone.\nEither increases toxicity of the other by sedation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estazolam",
            "description": {
                "common": "estazolam and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethanol",
            "description": {
                "common": "paliperidone and ethanol both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "exenatide injectable solution",
            "description": {
                "common": "paliperidone, exenatide injectable solution. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "exenatide injectable suspension",
            "description": {
                "common": "paliperidone, exenatide injectable suspension. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ezogabine",
            "description": {
                "common": "ezogabine, paliperidone.\nEither increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "felodipine",
            "description": {
                "common": "felodipine will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenfluramine",
            "description": {
                "common": "paliperidone increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl",
            "description": {
                "common": "fentanyl, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fesoterodine",
            "description": {
                "common": "fesoterodine decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flavoxate",
            "description": {
                "common": "flavoxate decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flecainide",
            "description": {
                "common": "flecainide and paliperidone both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flibanserin",
            "description": {
                "common": "flibanserin, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluconazole",
            "description": {
                "common": "fluconazole and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "fluoxetine and paliperidone both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "fluphenazine and paliperidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurazepam",
            "description": {
                "common": "flurazepam and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine and paliperidone both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "formoterol",
            "description": {
                "common": "formoterol and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "foscarnet",
            "description": {
                "common": "foscarnet and paliperidone both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostemsavir",
            "description": {
                "common": "paliperidone and fostemsavir both increase  QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "frovatriptan",
            "description": {
                "common": "frovatriptan, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ganaxolone",
            "description": {
                "common": "paliperidone and ganaxolone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemifloxacin",
            "description": {
                "common": "gemifloxacin and paliperidone both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemtuzumab",
            "description": {
                "common": "paliperidone and gemtuzumab both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glecaprevir/pibrentasvir",
            "description": {
                "common": "paliperidone will increase the level or effect of glecaprevir/pibrentasvir by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glimepiride",
            "description": {
                "common": "paliperidone, glimepiride. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "paliperidone, glipizide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "paliperidone, glyburide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glycopyrrolate",
            "description": {
                "common": "paliperidone increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glycopyrrolate inhaled",
            "description": {
                "common": "glycopyrrolate inhaled decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "guanfacine",
            "description": {
                "common": "guanfacine, paliperidone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "haloperidol and paliperidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "henbane",
            "description": {
                "common": "henbane decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "homatropine",
            "description": {
                "common": "homatropine decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydromorphone",
            "description": {
                "common": "hydromorphone and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyzine",
            "description": {
                "common": "hydroxyzine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hyoscyamine",
            "description": {
                "common": "hyoscyamine decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hyoscyamine spray",
            "description": {
                "common": "paliperidone increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "iloperidone and paliperidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "imipramine and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indacaterol, inhaled",
            "description": {
                "common": "indacaterol, inhaled, paliperidone. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "paliperidone, insulin aspart. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "paliperidone decreases effects of insulin degludec by Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; dose of antidiabetic agents may need adjustment and increased frequency of glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec/insulin aspart",
            "description": {
                "common": "paliperidone decreases effects of insulin degludec/insulin aspart by Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; dose of antidiabetic agents may need adjustment and increased frequency of glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "paliperidone, insulin detemir. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "paliperidone, insulin glargine. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "paliperidone, insulin glulisine. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "paliperidone decreases effects of insulin inhaled by Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; dose of antidiabetic agents may need adjustment and increased frequency of glucose monitoring may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "paliperidone, insulin lispro. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "paliperidone, insulin NPH. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "paliperidone, insulin regular human. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ipratropium",
            "description": {
                "common": "ipratropium decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoproterenol",
            "description": {
                "common": "paliperidone increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "istradefylline",
            "description": {
                "common": "istradefylline will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of P-gp substrates in clinical trials. Consider dose reduction of sensitive P-gp substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "itraconazole",
            "description": {
                "common": "itraconazole and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "ketoconazole will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketotifen, ophthalmic",
            "description": {
                "common": "paliperidone and ketotifen, ophthalmic both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lapatinib",
            "description": {
                "common": "lapatinib will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lasmiditan",
            "description": {
                "common": "lasmiditan, paliperidone.\nEither increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lemborexant",
            "description": {
                "common": "lemborexant, paliperidone.\nEither increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenvatinib",
            "description": {
                "common": "paliperidone and lenvatinib both increase  QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levalbuterol",
            "description": {
                "common": "paliperidone increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levofloxacin",
            "description": {
                "common": "levofloxacin and paliperidone both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levomilnacipran",
            "description": {
                "common": "levomilnacipran, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levorphanol",
            "description": {
                "common": "levorphanol and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "linezolid",
            "description": {
                "common": "linezolid, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "liraglutide",
            "description": {
                "common": "paliperidone, liraglutide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisdexamfetamine",
            "description": {
                "common": "paliperidone increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lithium",
            "description": {
                "common": "lithium, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofepramine",
            "description": {
                "common": "lofepramine and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofexidine",
            "description": {
                "common": "paliperidone and lofexidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomitapide",
            "description": {
                "common": "lomitapide increases levels of paliperidone by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Consider reducing dose when used concomitantly with lomitapide."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "lonafarnib will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Lonafarnib is a weak P-gp inhibitor. Monitor for adverse reactions if coadministered with P-gp substrates where minimal concentration changes may lead to serious or life-threatening toxicities. Reduce P-gp substrate dose if needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loprazolam",
            "description": {
                "common": "loprazolam and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loratadine",
            "description": {
                "common": "loratadine will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorazepam",
            "description": {
                "common": "lorazepam and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorcaserin",
            "description": {
                "common": "lorcaserin, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lormetazepam",
            "description": {
                "common": "lormetazepam and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lovastatin",
            "description": {
                "common": "lovastatin will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine",
            "description": {
                "common": "loxapine and paliperidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine inhaled",
            "description": {
                "common": "loxapine inhaled and paliperidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lumefantrine",
            "description": {
                "common": "lumefantrine and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "lurasidone, paliperidone.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maprotiline",
            "description": {
                "common": "maprotiline and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maraviroc",
            "description": {
                "common": "maraviroc, paliperidone.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "marijuana",
            "description": {
                "common": "paliperidone and marijuana both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meclizine",
            "description": {
                "common": "meclizine decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "melatonin",
            "description": {
                "common": "paliperidone and melatonin both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meperidine",
            "description": {
                "common": "meperidine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meprobamate",
            "description": {
                "common": "paliperidone and meprobamate both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metaproterenol",
            "description": {
                "common": "paliperidone increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metaxalone",
            "description": {
                "common": "metaxalone and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metformin",
            "description": {
                "common": "paliperidone, metformin. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methadone",
            "description": {
                "common": "methadone and paliperidone both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methamphetamine",
            "description": {
                "common": "paliperidone increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methocarbamol",
            "description": {
                "common": "methocarbamol and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methscopolamine",
            "description": {
                "common": "methscopolamine decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylenedioxymethamphetamine",
            "description": {
                "common": "paliperidone increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylergonovine",
            "description": {
                "common": "methylergonovine, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylphenidate",
            "description": {
                "common": "paliperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoclopramide",
            "description": {
                "common": "paliperidone and metoclopramide both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam",
            "description": {
                "common": "midazolam and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "midazolam intranasal, paliperidone.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midodrine",
            "description": {
                "common": "paliperidone increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone, paliperidone. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "miglitol",
            "description": {
                "common": "paliperidone, miglitol. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "milnacipran",
            "description": {
                "common": "milnacipran, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "paliperidone and mirtazapine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "modafinil",
            "description": {
                "common": "paliperidone increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "morphine",
            "description": {
                "common": "morphine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "motherwort",
            "description": {
                "common": "paliperidone and motherwort both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moxifloxacin",
            "description": {
                "common": "moxifloxacin and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moxonidine",
            "description": {
                "common": "paliperidone and moxonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nabilone",
            "description": {
                "common": "paliperidone and nabilone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nalbuphine",
            "description": {
                "common": "nalbuphine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naldemedine",
            "description": {
                "common": "paliperidone increases levels of naldemedine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor naldemedine for potential adverse effects if coadministered with P-gp inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naratriptan",
            "description": {
                "common": "naratriptan, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nateglinide",
            "description": {
                "common": "paliperidone, nateglinide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nicardipine",
            "description": {
                "common": "nicardipine will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nifedipine",
            "description": {
                "common": "nifedipine will decrease the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nilotinib",
            "description": {
                "common": "nilotinib will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nintedanib",
            "description": {
                "common": "paliperidone increases levels of nintedanib by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. If nintedanib adverse effects occur, management may require interruption, dose reduction, or discontinuation of therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "norepinephrine",
            "description": {
                "common": "paliperidone increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "nortriptyline and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "octreotide",
            "description": {
                "common": "octreotide and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "octreotide (Antidote)",
            "description": {
                "common": "octreotide (Antidote) and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofloxacin",
            "description": {
                "common": "ofloxacin and paliperidone both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olanzapine",
            "description": {
                "common": "olanzapine and paliperidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oliceridine",
            "description": {
                "common": "oliceridine, paliperidone.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olodaterol inhaled",
            "description": {
                "common": "paliperidone and olodaterol inhaled both increase  QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "onabotulinumtoxinA",
            "description": {
                "common": "onabotulinumtoxinA decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "opium tincture",
            "description": {
                "common": "opium tincture and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "orphenadrine",
            "description": {
                "common": "orphenadrine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "osilodrostat",
            "description": {
                "common": "osilodrostat and paliperidone both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "osimertinib",
            "description": {
                "common": "osimertinib and paliperidone both increase  QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxazepam",
            "description": {
                "common": "oxazepam and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxybutynin",
            "description": {
                "common": "oxybutynin decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxybutynin topical",
            "description": {
                "common": "oxybutynin topical decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxybutynin transdermal",
            "description": {
                "common": "oxybutynin transdermal decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxycodone",
            "description": {
                "common": "oxycodone and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxymorphone",
            "description": {
                "common": "oxymorphone and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ozanimod",
            "description": {
                "common": "ozanimod and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pancuronium",
            "description": {
                "common": "pancuronium decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "papaveretum",
            "description": {
                "common": "papaveretum and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "papaverine",
            "description": {
                "common": "paliperidone and papaverine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paroxetine",
            "description": {
                "common": "paliperidone and paroxetine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pasireotide",
            "description": {
                "common": "paliperidone and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentazocine",
            "description": {
                "common": "pentazocine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perphenazine",
            "description": {
                "common": "paliperidone and perphenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phendimetrazine",
            "description": {
                "common": "paliperidone increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenelzine",
            "description": {
                "common": "phenelzine, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phentermine",
            "description": {
                "common": "paliperidone increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenylephrine",
            "description": {
                "common": "paliperidone increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenylephrine PO",
            "description": {
                "common": "paliperidone increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.  ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin will decrease the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pholcodine",
            "description": {
                "common": "paliperidone and pholcodine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimozide",
            "description": {
                "common": "paliperidone and pimozide both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pioglitazone",
            "description": {
                "common": "paliperidone, pioglitazone. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pirbuterol",
            "description": {
                "common": "paliperidone increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "posaconazole",
            "description": {
                "common": "paliperidone and posaconazole both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pralidoxime",
            "description": {
                "common": "pralidoxime decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pramlintide",
            "description": {
                "common": "paliperidone, pramlintide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "procarbazine",
            "description": {
                "common": "procarbazine, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prochlorperazine",
            "description": {
                "common": "paliperidone and prochlorperazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "promazine",
            "description": {
                "common": "promazine and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "promethazine",
            "description": {
                "common": "paliperidone and promethazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propantheline",
            "description": {
                "common": "propantheline decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propofol",
            "description": {
                "common": "propofol and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propylhexedrine",
            "description": {
                "common": "paliperidone increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protriptyline",
            "description": {
                "common": "protriptyline and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quazepam",
            "description": {
                "common": "quazepam and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quercetin",
            "description": {
                "common": "quercetin will decrease the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quetiapine",
            "description": {
                "common": "paliperidone and quetiapine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinine",
            "description": {
                "common": "paliperidone and quinine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ramelteon",
            "description": {
                "common": "paliperidone and ramelteon both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ranolazine",
            "description": {
                "common": "ranolazine will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rapacuronium",
            "description": {
                "common": "rapacuronium decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "remimazolam",
            "description": {
                "common": "remimazolam, paliperidone.\nEither increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "repaglinide",
            "description": {
                "common": "paliperidone, repaglinide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Paliperidone dose may need to be increased when coadministered with strong inducers of both CYP3A4 and P-gp"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifaximin",
            "description": {
                "common": "paliperidone increases levels of rifaximin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rilpivirine",
            "description": {
                "common": "rilpivirine increases toxicity of paliperidone by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsade de Pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risperidone",
            "description": {
                "common": "paliperidone and risperidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rocuronium",
            "description": {
                "common": "rocuronium decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rosiglitazone",
            "description": {
                "common": "paliperidone, rosiglitazone. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salmeterol",
            "description": {
                "common": "paliperidone increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sarecycline",
            "description": {
                "common": "sarecycline will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor for toxicities of P-gp substrates that may require dosage reduction when coadministered with P-gp inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saxagliptin",
            "description": {
                "common": "paliperidone, saxagliptin. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "scopolamine",
            "description": {
                "common": "scopolamine decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "scullcap",
            "description": {
                "common": "paliperidone and scullcap both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selegiline",
            "description": {
                "common": "selegiline, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selpercatinib",
            "description": {
                "common": "selpercatinib increases toxicity of paliperidone by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "shepherd's purse",
            "description": {
                "common": "paliperidone and shepherd's purse both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "simvastatin",
            "description": {
                "common": "simvastatin will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sirolimus",
            "description": {
                "common": "sirolimus will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sitagliptin",
            "description": {
                "common": "paliperidone, sitagliptin. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of paliperidone by QTc interval. Use Caution/Monitor. Consider predose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of paliperidone by QTc interval. Use Caution/Monitor. Consider predose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "solifenacin",
            "description": {
                "common": "solifenacin decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sorafenib",
            "description": {
                "common": "sorafenib and paliperidone both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "St John's Wort will decrease the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Paliperidone dose may need to be increased when coadministered with strong inducers of both CYP3A4 and P-gp"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Consider reducing the dose of P-glycoprotein (P-gp) substrates, if adverse reactions are experienced when administered concomitantly with stiripentol."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sufentanil",
            "description": {
                "common": "sufentanil and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfamethoxazole",
            "description": {
                "common": "sulfamethoxazole and paliperidone both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sumatriptan",
            "description": {
                "common": "sumatriptan, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sumatriptan intranasal",
            "description": {
                "common": "sumatriptan intranasal, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "tacrolimus will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tapentadol",
            "description": {
                "common": "tapentadol and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "telavancin",
            "description": {
                "common": "paliperidone and telavancin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "temazepam",
            "description": {
                "common": "temazepam and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "terbutaline",
            "description": {
                "common": "paliperidone increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tetrabenazine",
            "description": {
                "common": "paliperidone and tetrabenazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thioridazine",
            "description": {
                "common": "paliperidone and thioridazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thiothixene",
            "description": {
                "common": "paliperidone and thiothixene both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tiotropium",
            "description": {
                "common": "tiotropium decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolazamide",
            "description": {
                "common": "paliperidone, tolazamide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "paliperidone, tolbutamide. Other (see comment). Use Caution/Monitor. \nComment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolterodine",
            "description": {
                "common": "tolterodine decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolvaptan",
            "description": {
                "common": "tolvaptan will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "topiramate",
            "description": {
                "common": "paliperidone and topiramate both increase  sedation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tramadol",
            "description": {
                "common": "tramadol and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "tranylcypromine, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trazodone",
            "description": {
                "common": "trazodone will decrease the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triazolam",
            "description": {
                "common": "triazolam and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triclabendazole",
            "description": {
                "common": "triclabendazole and paliperidone both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triclofos",
            "description": {
                "common": "triclofos and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "paliperidone and trifluoperazine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimethoprim",
            "description": {
                "common": "paliperidone and trimethoprim both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimipramine",
            "description": {
                "common": "trimipramine and paliperidone both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triprolidine",
            "description": {
                "common": "triprolidine and paliperidone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tropisetron",
            "description": {
                "common": "paliperidone and tropisetron both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trospium chloride",
            "description": {
                "common": "trospium chloride decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tucatinib",
            "description": {
                "common": "tucatinib will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Consider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valbenazine",
            "description": {
                "common": "valbenazine and paliperidone both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vecuronium",
            "description": {
                "common": "vecuronium decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "venlafaxine",
            "description": {
                "common": "paliperidone and venlafaxine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "verapamil",
            "description": {
                "common": "verapamil will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vilazodone",
            "description": {
                "common": "vilazodone, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, paliperidone.\nEither increases effects of the other by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voriconazole",
            "description": {
                "common": "paliperidone and voriconazole both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "xylometazoline",
            "description": {
                "common": "paliperidone increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "yohimbine",
            "description": {
                "common": "paliperidone increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ziconotide",
            "description": {
                "common": "paliperidone and ziconotide both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ziprasidone",
            "description": {
                "common": "paliperidone and ziprasidone both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zolmitriptan",
            "description": {
                "common": "zolmitriptan, paliperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zotepine",
            "description": {
                "common": "paliperidone and zotepine both increase  antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "azithromycin",
            "description": {
                "common": "azithromycin and paliperidone both increase  QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "brimonidine",
            "description": {
                "common": "brimonidine increases effects of paliperidone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chasteberry",
            "description": {
                "common": "chasteberry decreases effects of paliperidone by pharmacodynamic antagonism. Minor/Significance Unknown. (Theoretical interaction)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethanol",
            "description": {
                "common": "ethanol, paliperidone.\nEither increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eucalyptus",
            "description": {
                "common": "paliperidone and eucalyptus both increase  sedation. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pazopanib",
            "description": {
                "common": "paliperidone and pazopanib both increase  QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sage",
            "description": {
                "common": "paliperidone and sage both increase  sedation. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Upper respiratory tract infection",
            "percent": "12"
        },
        {
            "name": "Injection site reactions",
            "percent": "11"
        },
        {
            "name": "Injection site reaction",
            "percent": "12"
        },
        {
            "name": "Extrapyramidal symptoms",
            "percent": "7-20"
        },
        {
            "name": "Akathisia",
            "percent": "4-17"
        },
        {
            "name": "Tachycardia",
            "percent": "12-14"
        },
        {
            "name": "Headache",
            "percent": "11-14"
        },
        {
            "name": "Somnolence",
            "percent": "6-11"
        },
        {
            "name": "Somnolence",
            "percent": "9-26"
        },
        {
            "name": "Extrapyramidal symptoms",
            "percent": "4-23"
        },
        {
            "name": "Akathisia",
            "percent": "4-17"
        },
        {
            "name": "Vomiting",
            "percent": "6-11"
        },
        {
            "name": "Weight increased",
            "percent": "9"
        },
        {
            "name": "Headache",
            "percent": "7"
        },
        {
            "name": "Extrapyramidal symptoms",
            "percent": "7"
        },
        {
            "name": "Parkinsonism",
            "percent": "5"
        },
        {
            "name": "Akathisia",
            "percent": "4"
        },
        {
            "name": "Hyperkinesia",
            "percent": "4"
        },
        {
            "name": "Urinary tract infection",
            "percent": "3"
        },
        {
            "name": "Back pain",
            "percent": "3"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "3"
        },
        {
            "name": "Psychosis",
            "percent": "3"
        },
        {
            "name": "Anxiety",
            "percent": "3"
        },
        {
            "name": "Insomnia",
            "percent": "3"
        },
        {
            "name": "Diarrhea",
            "percent": "2"
        },
        {
            "name": "Dyskinesia",
            "percent": "2"
        },
        {
            "name": "Dystonia",
            "percent": "1"
        },
        {
            "name": "Weight increased",
            "percent": "10"
        },
        {
            "name": "Headache",
            "percent": "7"
        },
        {
            "name": "Parkinsonism",
            "percent": "4-6"
        },
        {
            "name": "Hyperkinesia",
            "percent": "5"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "5"
        },
        {
            "name": "Akathisia",
            "percent": "3-5"
        },
        {
            "name": "Tremor",
            "percent": "2"
        },
        {
            "name": "Dystonia",
            "percent": "1"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "10"
        },
        {
            "name": "Headache",
            "percent": "9"
        },
        {
            "name": "Weight increased",
            "percent": "9"
        },
        {
            "name": "Parkinsonism",
            "percent": "4-6"
        },
        {
            "name": "Hyperkinesia",
            "percent": "5"
        },
        {
            "name": "Akathisia",
            "percent": "3-5"
        },
        {
            "name": "Injection site reaction",
            "percent": "3"
        },
        {
            "name": "Urinary tract infection",
            "percent": "3"
        },
        {
            "name": "Dyskinesia",
            "percent": "1-3"
        },
        {
            "name": "Tremor",
            "percent": "1"
        },
        {
            "name": "Dystonia",
            "percent": "1"
        },
        {
            "name": "Salivary hypersecretion",
            "percent": "4"
        },
        {
            "name": "Upper abdominal pain",
            "percent": "1-3"
        },
        {
            "name": "Dry mouth",
            "percent": "1-3"
        },
        {
            "name": "Bundle branch block",
            "percent": "3"
        },
        {
            "name": "Sinus arrhythmia",
            "percent": "3"
        },
        {
            "name": "Atrioventricular",
            "percent": "1-2"
        },
        {
            "name": "AV",
            "percent": "1-2"
        },
        {
            "name": "block",
            "percent": "2"
        },
        {
            "name": "Fatigue",
            "percent": "6-9"
        },
        {
            "name": "Asthenia",
            "percent": "4-9"
        },
        {
            "name": "Tachycardia",
            "percent": "2-7"
        },
        {
            "name": "Anxiety",
            "percent": "2-6"
        },
        {
            "name": "Increased weight",
            "percent": "2-6"
        },
        {
            "name": "Salivary hypersecretion",
            "percent": "6"
        },
        {
            "name": "Dizziness",
            "percent": "4"
        },
        {
            "name": "Amenorrhea",
            "percent": "4"
        },
        {
            "name": "Galactorrhea",
            "percent": "3"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "3"
        },
        {
            "name": "Gynecomastia",
            "percent": "3"
        },
        {
            "name": "Blurred vision",
            "percent": "3"
        },
        {
            "name": "Dry mouth",
            "percent": "3"
        },
        {
            "name": "Swollen tongue",
            "percent": "3"
        },
        {
            "name": "Lethargy",
            "percent": "2-3"
        },
        {
            "name": "Tongue paralysis",
            "percent": "2-3"
        },
        {
            "name": "Asthenia",
            "percent": "2"
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Epistaxis",
            "percent": null
        },
        {
            "name": "Tremor",
            "percent": null
        },
        {
            "name": "Dyskinesia",
            "percent": null
        },
        {
            "name": "Urinary tract infection",
            "percent": null
        },
        {
            "name": "Blood and lymphatic system disorders",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Bradycardia",
            "percent": null
        },
        {
            "name": "tachycardia",
            "percent": null
        },
        {
            "name": "Ear and labyrinth disorders",
            "percent": null
        },
        {
            "name": "Vertigo",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "nausea",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Hepatobiliary disorders",
            "percent": null
        },
        {
            "name": "Transaminases increased",
            "percent": null
        },
        {
            "name": "Infections and infestations",
            "percent": null
        },
        {
            "name": "Cystitis",
            "percent": null
        },
        {
            "name": "respiratory tract infection",
            "percent": null
        },
        {
            "name": "tonsillitis",
            "percent": null
        },
        {
            "name": "Metabolism and nutritional disorders",
            "percent": null
        },
        {
            "name": "Decreased appetite",
            "percent": null
        },
        {
            "name": "increased appetite",
            "percent": null
        },
        {
            "name": "weight decreased",
            "percent": null
        },
        {
            "name": "Psychiatric disorders",
            "percent": null
        },
        {
            "name": "Depression",
            "percent": null
        },
        {
            "name": "Reproductive system and breast disorders",
            "percent": null
        },
        {
            "name": "Breast pain",
            "percent": null
        },
        {
            "name": "menstrual disorder",
            "percent": null
        },
        {
            "name": "Skin and SC tissue disorders",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Vascular disorders",
            "percent": null
        },
        {
            "name": "Hypertension",
            "percent": null
        },
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "AV block first degree",
            "percent": null
        },
        {
            "name": "bundle branch block",
            "percent": null
        },
        {
            "name": "palpitations",
            "percent": null
        },
        {
            "name": "postural orthostatic tachycardia syndrome",
            "percent": null
        },
        {
            "name": "Eye disorders",
            "percent": null
        },
        {
            "name": "Eye movement disorder",
            "percent": null
        },
        {
            "name": "eye rolling",
            "percent": null
        },
        {
            "name": "oculogyric crisis",
            "percent": null
        },
        {
            "name": "vision blurred",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Abdominal discomfort",
            "percent": null
        },
        {
            "name": "abdominal pain upper",
            "percent": null
        },
        {
            "name": "diarrhea",
            "percent": null
        },
        {
            "name": "dry mouth",
            "percent": null
        },
        {
            "name": "toothache",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Asthenia",
            "percent": null
        },
        {
            "name": "chest discomfort",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Hypersensitivity",
            "percent": null
        },
        {
            "name": "Investigations",
            "percent": null
        },
        {
            "name": "Electrocardiogram",
            "percent": null
        },
        {
            "name": "ECG",
            "percent": null
        },
        {
            "name": "abnormal",
            "percent": null
        },
        {
            "name": "Metabolism and nutrition disorders",
            "percent": null
        },
        {
            "name": "Hyperinsulinemia",
            "percent": null
        },
        {
            "name": "Musculoskeletal and connective tissue disorders",
            "percent": null
        },
        {
            "name": "Myalgia",
            "percent": null
        },
        {
            "name": "pain in extremity",
            "percent": null
        },
        {
            "name": "joint stiffness",
            "percent": null
        },
        {
            "name": "muscle spasms",
            "percent": null
        },
        {
            "name": "muscle twitching",
            "percent": null
        },
        {
            "name": "nuchal rigidity",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Bradykinesia",
            "percent": null
        },
        {
            "name": "cerebrovascular accident",
            "percent": null
        },
        {
            "name": "convulsion",
            "percent": null
        },
        {
            "name": "dizziness",
            "percent": null
        },
        {
            "name": "dizziness postural",
            "percent": null
        },
        {
            "name": "dysarthria",
            "percent": null
        },
        {
            "name": "hypertonia",
            "percent": null
        },
        {
            "name": "lethargy",
            "percent": null
        },
        {
            "name": "oromandibular dystonia",
            "percent": null
        },
        {
            "name": "psychomotor hyperactivity",
            "percent": null
        },
        {
            "name": "syncope",
            "percent": null
        },
        {
            "name": "Psychiatric disorders",
            "percent": null
        },
        {
            "name": "Agitation",
            "percent": null
        },
        {
            "name": "nightmare",
            "percent": null
        },
        {
            "name": "Reproductive system and breast disorders",
            "percent": null
        },
        {
            "name": "Breast discharge",
            "percent": null
        },
        {
            "name": "erectile dysfunction",
            "percent": null
        },
        {
            "name": "gynecomastia",
            "percent": null
        },
        {
            "name": "sexual dysfunction",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "thoracic",
            "percent": null
        },
        {
            "name": "and mediastinal disorders",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "Skin and SC tissue disorders",
            "percent": null
        },
        {
            "name": "Drug eruption",
            "percent": null
        },
        {
            "name": "eczema",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "pruritus generalized",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "Vascular disorders",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "orthostatic hypotension",
            "percent": null
        },
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Bradycardia",
            "percent": null
        },
        {
            "name": "palpitations",
            "percent": null
        },
        {
            "name": "Eye disorders",
            "percent": null
        },
        {
            "name": "Eye movement disorder",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Flatulence",
            "percent": null
        },
        {
            "name": "General disorders",
            "percent": null
        },
        {
            "name": "Edema",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Anaphylactic reaction",
            "percent": null
        },
        {
            "name": "Infections and infestations",
            "percent": null
        },
        {
            "name": "Urinary tract infection",
            "percent": null
        },
        {
            "name": "Investigations",
            "percent": null
        },
        {
            "name": "ALT",
            "percent": null
        },
        {
            "name": "AST increased",
            "percent": null
        },
        {
            "name": "Musculoskeletal and connective tissue disorders",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "pain in extremity",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Opisthotonos",
            "percent": null
        },
        {
            "name": "Psychiatric disorders",
            "percent": null
        },
        {
            "name": "Agitation",
            "percent": null
        },
        {
            "name": "insomnia",
            "percent": null
        },
        {
            "name": "nightmare",
            "percent": null
        },
        {
            "name": "Reproductive system and breast disorders",
            "percent": null
        },
        {
            "name": "Breast discomfort",
            "percent": null
        },
        {
            "name": "menstruation irregular",
            "percent": null
        },
        {
            "name": "retrograde ejaculation",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "thoracic",
            "percent": null
        },
        {
            "name": "and mediastinal disorders",
            "percent": null
        },
        {
            "name": "Nasal congestion",
            "percent": null
        },
        {
            "name": "Skin and SC tissue disorders",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "rash Vascular disorders",
            "percent": null
        },
        {
            "name": "Hypertension",
            "percent": null
        },
        {
            "name": "Anaphylactic reactions",
            "percent": null
        }
    ]
}